C15:0 Research: What the Studies Actually Show (and What They Don't)
Pentadecanoic acid has moved from an obscure dairy biomarker to a widely marketed supplement in about five years. This is a review of the C15:0 evidence as it stands in late 2026: the cell studies, the two human trials, the population data, and where the marketing has run ahead of the papers.
For the underlying biochemistry, see What Is C15:0? This article picks up where that one leaves off and asks the harder question: how good is the evidence?
The Evidence in Brief
- The cell data are real and fairly strong. In a twelve-system panel of human primary cells, C15:0 reduced a broad set of inflammatory, immune-activation and fibrotic markers, dose-dependently, with no cytotoxicity at any concentration tested.
- The human data are thin. Two small twelve-week randomized trials have been published. Both show that supplementation raises circulating C15:0. Neither has demonstrated a clinical outcome.
- The population data are associations. Higher circulating C15:0 tracks with better cardiometabolic outcomes in cohorts. It is also a marker of full-fat dairy intake.
- "Essential fatty acid" is a proposal, not a consensus. No major nutrition body has adopted it.
- Safety looks good. C15:0 holds Generally Recognized as Safe status for food use, and the trials reported no significant adverse events.
Where the C15:0 Research Comes From
Almost all of the primary C15:0 research traces back to one scientist, veterinary epidemiologist Stephanie Venn-Watson, who first noticed the fatty acid while studying aging in U.S. Navy dolphins. She went on to co-found Seraphina Therapeutics, the company behind the fatty15 supplement, and is lead author on the 2020, 2022, 2023 and 2024 papers that most C15:0 claims rest on. Patents are held on the compound, and part of the early work was funded by the U.S. Office of Naval Research.
That is not a reason to dismiss the work. The papers are peer-reviewed, the data are published, and the 2022 cell panel was run by an independent contract laboratory. It is a reason to read the papers rather than the press releases, because the two often say different things. This article does that.
The Cell Studies: What C15:0 Does to Human Cells
The best dataset on C15:0 is a 2022 screen using BioMAP, a platform used in pharmaceutical development to profile candidate compounds. A compound is added to twelve different cultures of human primary cells, each stimulated to mimic a type of tissue stress (vascular inflammation, allergic inflammation, T-cell activation, fibrosis, and so on), and 148 protein biomarkers are measured across the panel.
C15:0 was tested at four concentrations, from 1.9 to 50 µM, side by side with the omega-3 fatty acid EPA. The results:
- C15:0 showed dose-dependent activity in 10 of the 12 systems, with 36 significant activities in total.
- Most were reductions in inflammatory signals (IL-6, IL-1α, MCP-1, eotaxin-3), immune-activation markers (CD40, CD69, CD38), adhesion molecules (VCAM-1) and fibrotic markers (PAI-1, collagen I). A handful of markers rose.
- C15:0 was not cytotoxic in any system at any concentration. EPA, at 50 µM, was cytotoxic in four of the twelve.
In cells, C15:0 behaves like a broad, gentle anti-inflammatory with a clean safety profile. That is the strongest thing the research can currently say.
Separate laboratory work found that C15:0 is a dual partial agonist at PPARα and PPARδ, activates AMPK, inhibits mTOR, HDAC6 and JAK-STAT signaling, and lowered mitochondrial reactive oxygen species in stressed human liver cells at 10 to 50 µM. A 2023 comparison found its cell profile overlapped substantially with rapamycin. All of this is in vitro.
For the full panel marker by marker, including the two systems that showed no dose-dependent activity and the markers that moved at 17 µM but not across all doses, see our C15:0 research brief.
What Dr. Vosloo Emphasizes
In his October 2026 practitioner session, Dr. Vosloo framed C15:0 narrowly and structurally rather than as a broad metabolic agent.
The phospholipids rebuild the membrane; C15 helps it resist oxidative damage.
Four points he draws out of the literature:
- Stable by design. A saturated chain with no double bonds to oxidize, steadying membranes otherwise dominated by fragile polyunsaturated fats.
- Relevance to ferroptosis. The 2024 cellular stability hypothesis proposes that C15:0 strengthens membranes, supports mitochondrial repair, and resists iron-driven lipid peroxidation.
- Brain-relevant actions. C15:0 inhibits FAAH and MAO-B in cell assays, and a 2025 paper reports that aged dolphins develop human-like amyloid plaques, the model in which the fatty acid was first studied.
- A metabolic signal. Higher plasma C15:0 has been linked with better delayed recall in people with type 2 diabetes.
The same caution applies to all four. The ferroptosis and brain-pathway findings are cell assays and hypothesis papers; the delayed-recall finding is an association. None of them is a demonstrated clinical effect, and Dr. Vosloo presents them as reasons the molecule is worth including in a membrane formula rather than as outcomes to promise.
The Human Trials: What Happens When People Take C15:0
This is where most summaries get loose, so here is exactly what the trials found.
Trial 1: Young adults with overweight (2024)
Thirty adults aged 18 to 24 with overweight or obesity took 200 mg of C15:0 or placebo daily for twelve weeks. The primary endpoint was whether circulating levels rose. They did, with no significant adverse events.
The result that gets repeated comes from a secondary analysis. The investigators split the treated group in half by how high circulating C15:0 climbed. In the half that passed a threshold of 5 µg/mL, ALT fell by 29 U/L, AST by 6 U/L, and hemoglobin rose by 0.60 g/dL relative to the half that did not. That is a comparison of ten participants against ten, all of whom received C15:0. The authors called the finding "potentially relevant" and said it warrants further study.
You will see this trial described as showing that C15:0 "resulted in" lower liver enzymes and higher hemoglobin. The paper does not say that. It found a between-subgroup signal that a larger trial should test.
Trial 2: Women with fatty liver disease
A second twelve-week trial gave C15:0 to women with fatty liver disease who were also following a Mediterranean diet. Those who added C15:0 saw larger reductions in LDL cholesterol than diet alone, along with shifts in gut bacteria. Liver fat and body weight improved similarly in both arms, so the diet, not the supplement, drove the main result.
What has not been shown in people
No trial has yet shown that C15:0 supplementation improves energy, cognition, cardiovascular outcomes, longevity, or any disease endpoint. A larger trial in healthy older adults, looking at red blood cell health and markers of biological aging, is registered and under way.
The Population Studies: Why Researchers Got Interested
Long before anyone gave C15:0 as a supplement, large cohort studies kept finding the same pattern: people with more C15:0 in circulation had lower rates of type 2 diabetes, heart disease and heart failure over time. Those associations are consistent and they are what justified the cell and animal work.
They are also associations. Circulating C15:0 is a well-established marker of full-fat dairy intake, and people who eat full-fat dairy differ from those who do not in many ways. Whether C15:0 itself is doing the work, or is tagging along with a dietary pattern, is exactly what the trials are meant to settle and have not yet.
Is C15:0 an Essential Fatty Acid?
In 2020, Venn-Watson and colleagues proposed that C15:0 meets the criteria for an essential fatty acid, which would make it the first new one identified in roughly ninety years. A 2024 follow-up proposed a "cellular stability hypothesis" and a deficiency threshold of about 0.2% of total circulating fatty acids.
Both are hypothesis papers from the same research group. The claim has not been adopted by the National Academies, the European Food Safety Authority, the American Heart Association or any equivalent body, and classical deficiency studies, the kind that established the essentiality of omega-3 and omega-6 fats, have not been done. "Proposed essential" is the accurate phrase.
Is C15:0 Safe?
By the available evidence, yes. Purified C15:0 holds Generally Recognized as Safe status from the FDA for use in food. The cell panel found no cytotoxicity at any concentration. Both human trials reported no significant adverse events at 200 mg daily. And it is a fat humans have eaten, in dairy and ruminant meat, for as long as there have been dairy and ruminants.
Standard prescribing caution applies in pregnancy and lactation, alongside medications with known fat-soluble interactions, and in significant hepatic or renal impairment. Those are general considerations rather than signals arising from the C15:0 data itself.
How Much C15:0 Is in Food, and in Supplements?
C15:0 averages approximately 1.5% of total fatty acids in dairy fat, so a serving of full-fat dairy delivers tens of milligrams. Grass-finished beef carries more than grain-finished. The leading standalone supplement provides 100 mg per day; the 2024 trial used 200 mg.
Because C15:0 is a saturated fat with no double bonds, it is also one of the few membrane fats that does not oxidize readily, which is the property that makes it interesting alongside phospholipids rather than on its own.
C15:0 Where It Does Its Work
Phospholipid Synergy provides 100 mg of C15:0 per serving alongside phosphatidylcholine and the complementary phospholipids that cell membranes are actually built from. The phospholipids supply the building material; C15:0, with no oxidizable bonds, helps the membrane resist oxidative damage once it is rebuilt.
Our full C15:0 research brief lists every cell-panel result marker by marker, with the monitoring panel the published work used.
Visit the product page to learn more →How to Read C15:0 Claims
A few phrases to watch for, and what they usually mean:
- "36 cellular benefits." An accurate count of significant activities in the 2022 cell panel. Cells, not people.
- "Repairs mitochondrial function by 45%." We could not locate this figure in the primary papers. The published result is a reduction in mitochondrial reactive oxygen species in stressed liver cells.
- "Lowers 18+ cytokines." The paper counts 36 activities in both directions and does not give a clean cytokine tally.
- "Clinically shown to raise hemoglobin and lower liver enzymes." A between-subgroup signal in a 30-person trial, not a treatment effect against placebo.
- "The first essential fatty acid in 90 years." A proposal from the group that sells the supplement.
None of this makes C15:0 uninteresting. It makes it a promising fatty acid with good cell data, a clean safety record, and human evidence still being built. That is a sound reason to include it in a membrane formula, and a poor reason to promise anyone a result.
Where This Leaves C15:0
The honest summary of the C15:0 research in 2026 is that the laboratory case is well made, the human case is at an early stage, and the two are frequently blurred in the way the molecule is marketed. We think the science is strong enough to stand without that blurring, which is why we added C15:0 to Phospholipid Synergy at 100 mg per serving, the standard daily amount used in the leading standalone product, placed it alongside the phospholipids it is meant to help stabilize, and published the full brief so you can check our reading against the papers.
For the structural side of the story, see the benefits of phospholipids and what phospholipids are.
Frequently Asked Questions About C15:0 Research
Does C15:0 actually work?
Has C15:0 been tested in humans?
Is C15:0 the same as fatty15?
What does the research say about C15:0 and the liver?
What is the difference between C15:0 and omega-3?
Can you get enough C15:0 from food?
References
- Venn-Watson S, Butterworth CN. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3. PLoS One. 2022;17(5):e0268778. doi:10.1371/journal.pone.0268778
- Venn-Watson S, Lumpkin R, Dennis EA. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Sci Rep. 2020;10:8161. doi:10.1038/s41598-020-64960-y
- Venn-Watson S, Schork NJ. Pentadecanoic acid (C15:0) shares clinically relevant cell-based activities with leading longevity-enhancing compounds. Nutrients. 2023;15(21):4607. doi:10.3390/nu15214607
- Robinson MK, et al. Pentadecanoic acid supplementation in young adults with overweight and obesity: a randomized controlled trial. J Nutr. 2024;154(9):2763-2771. doi:10.1016/j.tjnut.2024.07.030
- Venn-Watson S. The cellular stability hypothesis. Metabolites. 2024;14(7):355. doi:10.3390/metabo14070355
- Venn-Watson S, et al. Amyloid in dolphins and C15:0. Int J Mol Sci. 2025. Cited in Dr. Vosloo's October 2026 practitioner session.
- ClinicalTrials.gov NCT07812792. Effect of pentadecanoic acid supplementation on red blood cell health and biological aging in healthy older adults. clinicaltrials.gov/study/NCT07812792
Medical Disclaimer: We are not medical professionals, and the information provided in this article is intended for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any questions you may have about a medical condition, symptoms, or treatment options. Never disregard or delay seeking professional medical advice based on information contained in this communication. Reliance on any information provided in this article is solely at your own risk. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.